C a s e R e p o r t e240
I NTRO D U C TIO N
The endoscopic deployment of self-expanding metallic stents (SEMS) for palliation of malignant gastric outlet obstruction (GOO) was first described by Truong et al in 1992.
(1) Since then, numerous studies have demonstrated the advantages and efficacy of this palliative treatment option, which has relatively high success rates and low procedure-associated morbidity and mortality. (2) In the presence of an inoperable disease, enteral stenting is a simple yet safe treatment option to relieve obstructive symptoms and enable oral nutrition. However, common complications include stent obstruction and migration. Stent obstruction was found to be largely secondary to malignant tumour ingrowth, (2) while other causes include malfunction, fracture, and even large impacted food boluses. (3) In such cases, therapeutic options include: (a) the removal of the occluded stent and redeployment of another in its place; (b) the coaxial placement of a second stent within the first stent, also described as secondary stent-in-stent SEMS placement; and (c) palliative surgical bypass.
Herein, we report a case of early in-stent occlusion due to ingrowth of soft oedematous mucosal tissue through the lattices of an uncovered stent, which was used for palliation of a postoperative gastrojejunal anastomotic stricture. This was subsequently successfully treated using secondary stent-in-stent SEMS placement.
CA S E R EPO RT
A 62-year-old man underwent a palliative subtotal gastrectomy with Bilroth II gastrojejunostomy for a locally advanced gastric adenocarcinoma, classified as signet ring cell type using
World Health Organization's histologic classification of gastric tumours. Secondary stent-in-stent self-expanding metallic stent placement for early stent occlusion due to mucosal oedema in the gastrojejunal anastomosis after palliative subtotal gastrectomy for locally advanced gastric cancer improvement was reported after the procedure, and the patient was progressed to feed and a finely minced diet. However, he experienced recurrent symptoms of GOO four days later.
Abdominal radiography showed a well-placed enteral stent, with no evidence of stent migration or stenosis (Fig. 2 ).
Hence, a repeat gastroscopy was performed, with the possibility of argon plasma coagulation of the ingrowing tumour tissue that may be causing the in-stent occlusion. Although the stent was observed to still be in good position, oedematous small bowel mucosa was seen passing through the stent lattices, causing in-stent obstruction (Fig. 3a) . The scope could be easily passed beyond the obstruction with minimal resistance (Fig. 3b) . The oedematous mucosa ingrowth was soft in consistency. As the mucosa ingrowth was likely benign based on its clinical appearance and soft consistency, no biopsy was performed. In addition, as it was not a hard tumour ingrowth, argon plasma coagulation was not indicated in this clinical setting.
A stent-in-stent procedure was performed using a 100-mm He was uneventfully progressed to a blended diet, and was discharged well three days after the stent-in-stent procedure.
He has since been started on palliative chemotherapy, and the double stents have remained clinically patent for more than eight weeks.
D I SCU S S IO N
Malignant GOO is a late complication of gastric, duodenal, pancreatic and biliary malignancies. Therapeutic options include surgical bypass, and more recently, the use of SEMS.
A meta-analysis on endoscopic and surgical procedures for GOO palliation showed that endoscopic stenting had better outcomes in terms of clinical success, and reduction in procedure-related morbidity, mortality and length of hospital stay. (7) The placement of SEMS in the palliation of a recurrent malignant obstruction (due to anastomotic stricture or local tumour recurrence after gastric surgery) has been shown to be technically feasible and clinically effective. (8) Although there have been concerns about the clinical use of SEMS in peritoneal carcinomatosis due to the risk of multifocal obstruction, (9) a study by Mendelsohn et al (10) showed similar clinical outcomes in the group with and without carcinomatosis (clinical success rates of 81% and 84%, respectively). In the present case, we opted for SEMS even though our patient had peritoneal carcinomatosis, as the obstruction was identified to be at the gastrojejunal site, with the other obstruction in the large bowel already bypassed.
In several prospective studies, the stent patency time, failure rate and reintervention rate of both covered and uncovered stents were found to be comparable. (11) Although uncovered stents are favoured, mainly due to the low risk of dislodgement and migration, (12) local tissue hyperplasia as well as ingrowth of tumour and oedematous tissue through the fenestrations of uncovered stents can lead to stent failure. Covered stents, however, are associated with a slightly higher incidence of migration after deployment.
In the present case, a WallFlex ® uncovered duodenal stent was deployed first. This stent is made of nitinol, an alloy of nickel and titanium. Nitinol has increased flexibility, which is helpful for stenting sharply angulated regions, but this is at the cost of a lesser radial force, relative to stents made with other metals. (13) The decision to first use an uncovered stent was due to several reasons. Firstly, most commonly available pyloric or enteral stents are uncovered. Also, a stent deployed at such a location (i.e. at the efferent limb of the gastrojejunal outcome of double stent placement will require larger case series and clinical trials. (16, 17) Since various types of enteral stents with diverse functional characteristics are available to the physician, the choice of stents for placement should be tailored to each patient.
